AU2022244439A1 - Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer - Google Patents

Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer Download PDF

Info

Publication number
AU2022244439A1
AU2022244439A1 AU2022244439A AU2022244439A AU2022244439A1 AU 2022244439 A1 AU2022244439 A1 AU 2022244439A1 AU 2022244439 A AU2022244439 A AU 2022244439A AU 2022244439 A AU2022244439 A AU 2022244439A AU 2022244439 A1 AU2022244439 A1 AU 2022244439A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
androgen
talazoparib
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022244439A
Other languages
English (en)
Inventor
Akos Gabor CZIBERE
Dana Ann Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Pfizer Inc
Original Assignee
Astellas Pharma Inc
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Pfizer Inc filed Critical Astellas Pharma Inc
Publication of AU2022244439A1 publication Critical patent/AU2022244439A1/en
Priority to AU2025210784A priority Critical patent/AU2025210784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022244439A 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer Abandoned AU2022244439A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025210784A AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163165723P 2021-03-24 2021-03-24
US63/165,723 2021-03-24
US202163282163P 2021-11-22 2021-11-22
US63/282,163 2021-11-22
US202263317368P 2022-03-07 2022-03-07
US63/317,368 2022-03-07
PCT/IB2022/052536 WO2022200982A1 (en) 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025210784A Division AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Publications (1)

Publication Number Publication Date
AU2022244439A1 true AU2022244439A1 (en) 2023-09-28

Family

ID=80952181

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022244439A Abandoned AU2022244439A1 (en) 2021-03-24 2022-03-21 Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
AU2025210784A Pending AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025210784A Pending AU2025210784A1 (en) 2021-03-24 2025-07-30 Combination of talazoparib and an anti-androgen for the treatment of DDR gene mutated metastatic castration-sensitive prostate cancer

Country Status (9)

Country Link
US (1) US20240180906A1 (https=)
EP (1) EP4313034A1 (https=)
JP (1) JP2024510666A (https=)
KR (1) KR20230159510A (https=)
AU (2) AU2022244439A1 (https=)
BR (1) BR112023018906A2 (https=)
CA (1) CA3214316A1 (https=)
MX (1) MX2023011294A (https=)
WO (1) WO2022200982A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
CN104478875B (zh) 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
SG173837A1 (en) 2009-02-24 2011-09-29 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
EP2531033A4 (en) 2010-02-03 2013-07-31 Biomarin Pharm Inc POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
KR20190120458A (ko) 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
CN105916846A (zh) 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
SG11201803462PA (en) 2015-10-26 2018-05-30 Medivation Tech Llc Treatment of small cell lung cancer with a parp inhibitor
HUE060460T2 (hu) * 2017-04-13 2023-03-28 Janssen Pharmaceutica Nv Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére
CA3078806A1 (en) * 2017-10-13 2019-04-18 Merck Patent Gmbh Combination of a parp inhibitor and a pd-1 axis binding antagonist

Also Published As

Publication number Publication date
EP4313034A1 (en) 2024-02-07
AU2025210784A1 (en) 2025-08-21
CA3214316A1 (en) 2022-09-29
JP2024510666A (ja) 2024-03-08
BR112023018906A2 (pt) 2023-10-10
KR20230159510A (ko) 2023-11-21
US20240180906A1 (en) 2024-06-06
WO2022200982A1 (en) 2022-09-29
MX2023011294A (es) 2023-10-05

Similar Documents

Publication Publication Date Title
AU2022244439A1 (en) Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP3721906A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20240000783A1 (en) Combination therapy
US20250090514A1 (en) Method of treating cancer
WO2024127140A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
AU2023357890A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
KR20230008783A (ko) 아비라테론 아세테이트 및 니라파립의 약제학적 제형
HK40098285A (zh) 用於治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
CN117098535A (zh) 用于治疗ddr基因突变转移性去势敏感性前列腺癌的他拉唑帕尼与抗雄激素的组合
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2026078619A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078615A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2025210510A1 (en) Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor
HK40096012A (zh) 组合疗法
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
EA049014B1 (ru) Способ лечения рака

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted